JeremyPCetnarMD

Oncology • Portland, OR

Medical Oncologist in Portland, Oregon at ohsu

Join to view full profile

Dr. Cetnar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cetnar's full profile

Already have an account?

Office
3181 Sw Sam Jackson Park Rd
Portland, OR 97239
Phone+1 503-494-6346

Fax+1 608-266-6020

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2006 - 2009
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2002 - 2005
Loyola University Chicago Stritch School of MedicineClass of 2002

Certifications & Licensure

OR State Medical License 2013 - 2025
WI State Medical License 2009 - 2013
PA State Medical License 2006 - 2010
MN State Medical License 2005 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
ACTIVE_NOT_RECRUITING
PHASE3
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Start of enrollment: 2015 May 06
ACTIVE_NOT_RECRUITING
PHASE3
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Start of enrollment: 2018 Jun 25
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

6 citations
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refu...
Petros Grivas, Vadim S Koshkin, Xiangying Chu, Suzanne Cole, Rohit K Jain
European Urology Oncology. 2024-08-01
1 citations
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez-Kozlova, Kevin G Chan
Nature Medicine. 2024-04-01
42 citations
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Matthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez-Kozlova, Kevin G Chan
Nature Medicine. 2023-11-01

Press Mentions

Stronger Rules Needed for Oncology Financial Conflicts of Interest, Critics ArgueMay 2nd, 2024
Gemcitabine, Cisplatin, plus Nivolumab in Patients with Muscle-Invasive Bladder Cancer with Selective Bladder SparingJune 15th, 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member